Preclinical Partnerships BlossomHill's pan KRAS inhibitor programs and macrocyclic cancer compounds create strong opportunities for CROs and pharma to collaborate on early preclinical studies, ADME/Tox profiling, and in vivo efficacy to accelerate IND timelines.

Licensing Opportunities Their first in class macrocyclic OMNI EGFR inhibitor for NSCLC and ongoing pan KRAS programs position BlossomHill as a potential licensing or co development target for oncology companies seeking innovative KRAS or EGFR modalities; upcoming AACR presentations provide visibility for deal diligence.

Financing Readiness With an eighty four million financing in 2025 and total funding around one hundred million, plus the appointment of a new chief financial officer, BlossomHill appears poised for partnership deals with upfronts and milestones to de-risk pipeline progression.

Strategic Events Active engagement at industry events such as AACR and JP Morgan creates timely touchpoints to reach potential licensees, strategic investors, and deal partners during high visibility windows.

Regional Ecosystem Headquartered in San Diego, BlossomHill can leverage a robust local biotech network for collaboration with contract manufacturers, CROs, and academic translational partners to accelerate early stage oncology and autoimmune programs.